Investor · 1 deal
Eli Lilly and Company
Disclosed deals
Every published round Eli Lilly and Company took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AdvanCell | Series D+ | 15 Jul 2026 | $450m | Participant | Forbes Australia (3 Sep 2026), Forbes Australia (16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio |
Portfolio
Companies Eli Lilly and Company has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | Produces radiopharmaceuticals that target cancer cells without the typical collateral dam… | 15 Jul 2026, Series D+ | 1 | 0 |
Funds
Fund closes reported for Eli Lilly and Company, as distinct from the investments it has made.
Portfolio companies acquired
Companies Eli Lilly and Company has backed that another company then bought. An exit for the holding, not a deal Eli Lilly and Company did.
People
Coverage
Stories naming Eli Lilly and Company. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
No coverage collected yet.